Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta

Hypertension

Volumn 70, Issue 5, 2017, Pages 1014-1024

  Kaitu'U Lino, Tu'Uhevaha J ^a,b   Brownfoot, Fiona C ^a,b   Hastie, Roxanne ^a,b   Chand, Ashwini ^c   Cannon, Ping ^a,b   Deo, Minh ^a,b   Tuohey, Laura ^a,b   Whitehead, Clare ^a,b   Hannan, Natalie J ^a,b   Tong, Stephen ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MERCY HOSPITAL FOR WOMEN   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

Author keywords

cytokines; hypoxia; inflammation; placenta; preeclampsia

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; ENDOGLIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MATRIX METALLOPROTEINASE 14; PROTEIN TYROSINE KINASE; SOLUBLE ENDOGLIN; SOLUBLE FMS LIKE TYROSINE KINASE 1; STROMELYSIN; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN RECEPTOR 1;

ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTROPHOBLAST; ENDOPLASMIC RETICULUM; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; HUVEC CELL LINE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHENOTYPE; PLACENTA; PLACENTA TISSUE; PREECLAMPSIA; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNCYTIOTROPHOBLAST; ADULT; ANIMAL; BLOOD; GENE EXPRESSION; HYPOXIA; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; PLACENTA DISEASES; PRE-ECLAMPSIA; PREGNANCY; SECRETION (PROCESS); STATISTICS; VASCULARIZATION;

ACTIVATING TRANSCRIPTION FACTOR 3; ADULT; ANIMALS; ENDOGLIN; FEMALE; GENE EXPRESSION; HUMANS; HYPOXIA; INFLAMMATION; MICE; PLACENTA; PLACENTA DISEASES; PRE-ECLAMPSIA; PREGNANCY; STATISTICS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 85031779302     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.117.09548     Document Type: Article

References (43)

1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785-799. doi: 10.1016/S0140-6736(05)17987-2.
2. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308:1592-1594. doi: 10.1126/science.1111726.
3. Silasi M, Cohen B, Karumanchi SA, Rana S. Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet Gynecol Clin North Am. 2010;37:239-253. doi: 10.1016/j.ogc.2010.02.013.
4. Germain SJ, Sacks GP, Sooranna SR, Soorana SR, Sargent IL, Redman CW. Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. J Immunol. 2007;178:5949-5956.
5. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999;180(2 pt 1):499-506.
6. Austgulen R, Lien E, Liabakk NB, Jacobsen G, Arntzen KJ. Increased levels of cytokines and cytokine activity modifiers in normal pregnancy. Eur J Obstet Gynecol Reprod Biol. 1994;57:149-155.
7. Kupferminc MJ, Peaceman AM, Wigton TR, Tamura RK, Rehnberg KA, Socol ML. Immunoreactive tumor necrosis factor-Alpha is elevated in maternal plasma but undetected in amniotic fluid in the second trimester. Am J Obstet Gynecol. 1994;171:976-979.
8. Greer IA, Lyall F, Perera T, Boswell F, Macara LM. Increased concentrations of cytokines interleukin-6 and interleukin-1 receptor antagonist in plasma of women with preeclampsia: a mechanism for endothelial dysfunction? Obstet Gynecol. 1994;84:937-940.
9. Kupferminc MJ, Peaceman AM, Wigton TR, Rehnberg KA, Socol ML. Tumor necrosis factor-Alpha is elevated in plasma and amniotic fluid of patients with severe preeclampsia. Am J Obstet Gynecol. 1994;170:1752-1757; discussion 1757-1759.
10. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-658. doi: 10.1172/JCI17189.
11. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642-649. doi: 10.1038/nm1429.
12. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol. 2010;5:173-192. doi: 10.1146/annurev-pathol-121808-102149.
13. Whitehead CL, Walker SP, Ye L, Mendis S, Kaitu'u-Lino TJ, Lappas M, Tong S. Placental specific mRNA in the maternal circulation are globally dysregulated in pregnancies complicated by fetal growth restriction. J Clin Endocrinol Metab. 2013;98:E429-E436. doi: 10.1210/jc.2012-2468.
14. Thompson MR, Xu D, Williams BR. ATF3 transcription factor and its emerging roles in immunity and cancer. J Mol Med (Berl). 2009;87:1053-1060. doi: 10.1007/s00109-009-0520-x.
15. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81:1-5. doi: 10.1189/jlb.0306164.
16. Gilchrist M, Thorsson V, Li B, Rust AG, Korb M, Roach JC, Kennedy K, Hai T, Bolouri H, Aderem A. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature. 2006;441:173-178. doi: 10.1038/nature04768.
17. Whitmore MM, Iparraguirre A, Kubelka L, Weninger W, Hai T, Williams BR. Negative regulation of TLR-signaling pathways by activating transcription factor-3. J Immunol. 2007;179:3622-3630.
18. Hartman MG, Lu D, Kim ML, Kociba GJ, Shukri T, Buteau J, Wang X, Frankel WL, Guttridge D, Prentki M, Grey ST, Ron D, Hai T. Role for activating transcription factor 3 in stress-induced betacell apoptosis. Mol Cell Biol. 2004;24:5721-5732. doi: 10.1128/MCB.24.13.5721-5732.2004.
19. Moslehi R, Mills JL, Signore C, Kumar A, Ambroggio X, Dzutsev A. Integrative transcriptome analysis reveals dysregulation of canonical cancer molecular pathways in placenta leading to preeclampsia. Sci Rep. 2013;3:2407. doi: 10.1038/srep02407.
20. The ACOG Task Force. American College of Obstetricians and Gynecologists guidelines, 2013. https://www.acog.org/Resources-And-Publications/Task-Force-And-Work-Group-Reports/Hypertension-in-Pregnancy. Accessed March 10, 2014.
21. Whitehead CL, Palmer KR, Nilsson U, Gao Y, Saglam B, Lappas M, Tong S. Placental expression of a novel primate-specific splice variant of sFlt-1 is upregulated in pregnancies complicated by severe early onset pre-eclampsia. BJOG. 2011;118:1268-1271. doi: 10.1111/j.1471-0528. 2011.02962.x.
22. Brownfoot FC, Hannan N, Onda K, Tong S, Kaitu'u-Lino T. Soluble endoglin production is upregulated by oxysterols but not quenched by pravastatin in primary placental and endothelial cells. Placenta. 2014;35:724-731. doi: 10.1016/j.placenta.2014.06.374.
23. Brownfoot FC, Hastie R, Hannan NJ, Cannon P, Tuohey L, Parry LJ, Senadheera S, Illanes SE, Kaitu'u-Lino TJ, Tong S. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol. 2016;214:356.e1-356.e15. doi: 10.1016/j.ajog.2015.12.019.
24. Brownfoot FC, Tong S, Hannan NJ, Binder NK, Walker SP, Cannon P, Hastie R, Onda K, Kaitu'u-Lino TJ. Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia. Hypertension. 2015;66:687-697; discussion 445. doi: 10.1161/HYPERTENSIONAHA.115.05445.
25. Onda K, Tong S, Beard S, et al. Proton pump inhibitors decrease soluble fms-like tyrosine kinase-1 and soluble endoglin secretion, decrease hypertension, and rescue endothelial dysfunction. Hypertension. 2017;69:457-468. doi: 10.1161/HYPERTENSIONAHA.116.08408.
26. Kaitu'u-Lino TJ, Tong S, Beard S, Hastie R, Tuohey L, Brownfoot F, Onda K, Hannan NJ. Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin. Pregnancy Hypertens. 2014;4:287-295. doi: 10.1016/j.preghy.2014.09.003.
27. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992-1005. doi: 10.1056/NEJMoa055352.
28. Scharfe-Nugent A, Corr SC, Carpenter SB, Keogh L, Doyle B, Martin C, Fitzgerald KA, Daly S, O'Leary JJ, O'Neill LA. TLR9 provokes inflammation in response to fetal DNA: mechanism for fetal loss in preterm birth and preeclampsia. J Immunol. 2012;188:5706-5712. doi: 10.4049/jimmunol.1103454.
29. Kaitu'u-Lino TJ, Palmer KR, Whitehead CL, Williams E, Lappas M, Tong S. MMP-14 is expressed in preeclamptic placentas and mediates release of soluble endoglin. Am J Pathol. 2012;180:888-894. doi: 10.1016/j.ajpath.2011.11.014.
30. Jung JJ, Tiwari A, Inamdar SM, Thomas CP, Goel A, Choudhury A. Secretion of soluble vascular endothelial growth factor receptor 1 (sVEGFR1/sFlt1) requires Arf1, Arf6, and Rab11 GTPases. PLoS One. 2012;7:e44572. doi: 10.1371/journal.pone.0044572.
31. Gratton AM, Ye L, Brownfoot FC, Hannan NJ, Whitehead C, Cannon P, Deo M, Fuller PJ, Tong S, Kaitu'u-Lino TJ. Steroid sulfatase is increased in the placentas and whole blood of women with early-onset preeclampsia. Placenta. 2016;48:72-79. doi: 10.1016/j.placenta.2016.10.008.
32. Macintire K, Tuohey L, Ye L, Palmer K, Gantier M, Tong S, Kaitu'u-Lino TJ. PAPPA2 is increased in severe early onset pre-eclampsia and upregulated with hypoxia. Reprod Fertil Dev. 2014;26:351-357. doi: 10.1071/RD12384.
33. Paiva P, Whitehead C, Saglam B, Palmer K, Tong S. Measurement of mRNA transcripts of very high placental expression in maternal blood as biomarkers of preeclampsia. J Clin Endocrinol Metab. 2011;96:E1807-E1815. doi: 10.1210/jc.2011-1233.
34. Tuohey L, Macintire K, Ye L, Palmer K, Skubisz M, Tong S, Kaitu'u-Lino TJ. PLAC4 is upregulated in severe early onset preeclampsia and upregulated with syncytialisation but not hypoxia. Placenta. 2013;34:256-260. doi: 10.1016/j.placenta.2012.12.009.
35. Sitras V, Paulssen RH, Grønaas H, Leirvik J, Hanssen TA, Vartun A, Acharya G. Differential placental gene expression in severe preeclampsia. Placenta. 2009;30:424-433. doi: 10.1016/j.placenta.2009.01.012.
36. Zamudio S, Wu Y, Ietta F, Rolfo A, Cross A, Wheeler T, Post M, Illsley NP, Caniggia I. Human placental hypoxia-inducible factor-1alpha expression correlates with clinical outcomes in chronic hypoxia in vivo. Am J Pathol. 2007;170:2171-2179.
37. Gilbert J, Dukes M, LaMarca B, Cockrell K, Babcock S, Granger J. Effects of reduced uterine perfusion pressure on blood pressure and metabolic factors in pregnant rats. Am J Hypertens. 2007;20:686-691. doi: 10.1016/j.amjhyper.2006.12.016.
38. Makris A, Thornton C, Thompson J, Thomson S, Martin R, Ogle R, Waugh R, McKenzie P, Kirwan P, Hennessy A. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int. 2007;71:977-984. doi: 10.1038/sj.ki.5002175.
39. Ching T, Song MA, Tiirikainen M, Molnar J, Berry M, Towner D, Garmire LX. Genome-wide hypermethylation coupled with promoter hypomethylation in the chorioamniotic membranes of early onset preeclampsia. Mol Hum Reprod. 2014;20:885-904. doi: 10.1093/molehr/gau046.
40. Ameri K, Hammond EM, Culmsee C, Raida M, Katschinski DM, Wenger RH, Wagner E, Davis RJ, Hai T, Denko N, Harris AL. Induction of activating transcription factor 3 by anoxia is independent of p53 and the hypoxic HIF signalling pathway. Oncogene. 2007;26:284-289. doi: 10.1038/sj.onc.1209781.
41. Jebbink J, Keijser R, Veenboer G, van der Post J, Ris-Stalpers C, Afink G. Expression of placental FLT1 transcript variants relates to both gestational hypertensive disease and fetal growth. Hypertension. 2011;58:70-76. doi: 10.1161/HYPERTENSIONAHA.110.164079.
42. Palmer KR, Kaitu'u-Lino TJ, Cannon P, Tuohey L, De Silva MS, Varas-Godoy M, Acuna S, Galaz J, Tong S, Illanes SE. Maternal plasma concentrations of the placental specific sflt-1 variant, sflt-1 e15a, in fetal growth restriction and preeclampsia. J Mat Fet Neonatal Med. 2016:1-5.
43. BioGPS. Gene Portal System [website]. http://biogps.org. Accessed March 10, 2014.